Omecamtiv mecarbil

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 510321

CAS#: 873697-71-3

Description: Omecamtiv mecarbil, also known as CK-1827452, is a cardiac specific myosin activator. It is clinically tested for its role in the treatment of left ventricular systolic heart failure. Omecamtiv Mecarbil specifically targets and activates myocardial ATPase and improves energy utilization. Omecamtiv Mecarbil improves systolic function by increasing the systolic ejection duration/stroke volume, without consuming more ATP energy, oxygen or altering intracellular calcium levels causing an overall improvement in cardiac efficiency. (source:

Chemical Structure

Omecamtiv mecarbil
CAS# 873697-71-3

Theoretical Analysis

MedKoo Cat#: 510321
Name: Omecamtiv mecarbil
CAS#: 873697-71-3
Chemical Formula: C20H24FN5O3
Exact Mass: 401.1863
Molecular Weight: 401.43
Elemental Analysis: C, 59.84; H, 6.03; F, 4.73; N, 17.45; O, 11.96

Price and Availability

Size Price Availability Quantity
10.0mg USD 150.0 2 Weeks
25.0mg USD 250.0 2 Weeks
50.0mg USD 450.0 2 Weeks
100.0mg USD 750.0 2 Weeks
200.0mg USD 1250.0 2 Weeks
500.0mg USD 2050.0 2 Weeks
1.0g USD 3450.0 2 Weeks
2.0g USD 5250.0 2 Weeks
5.0g USD 8650.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: Omecamtiv mecarbil; CK1827452; CK 1827452; CK1827452.

IUPAC/Chemical Name: methyl 4-(2-fluoro-3-(3-(6-methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylate


InChi Code: InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 401.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

 1: Spinarova L, Spinar J. Pharmacotherapy of dilated cardiomyopathy. Curr Pharm Des. 2014;21(4):449-58. PubMed PMID: 25483945.

2: Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik FI, Wolff AA, Shaburishvili T. Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina. JACC Heart Fail. 2014 Nov 11. pii: S2213-1779(14)00379-5. doi: 10.1016/j.jchf.2014.07.009. [Epub ahead of print] PubMed PMID: 25453536.

3: McNeice AH, McAleavey NM, Menown IB. Advances in clinical cardiology. Adv Ther. 2014 Aug;31(8):837-60. doi: 10.1007/s12325-014-0141-9. Epub 2014 Jul 30. PubMed PMID: 25074280.

4: Wang Y, Ajtai K, Burghardt TP. Analytical comparison of natural and pharmaceutical ventricular myosin activators. Biochemistry. 2014 Aug 19;53(32):5298-306. doi: 10.1021/bi500730t. Epub 2014 Aug 7. PubMed PMID: 25068717; PubMed Central PMCID: PMC4139156.

5: Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, Hilfiker-Kleiner D, Hirsch E, Iaccarino G, Knöll R, Leite-Moreira AF, Lourenço AP, Mayr M, Thum T, Tocchetti CG. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2014 May;16(5):494-508. doi: 10.1002/ejhf.62. Epub 2014 Mar 17. PubMed PMID: 24639064.

6: Shintani SA, Oyama K, Kobirumaki-Shimozawa F, Ohki T, Ishiwata S, Fukuda N. Sarcomere length nanometry in rat neonatal cardiomyocytes expressed with α-actinin-AcGFP in Z discs. J Gen Physiol. 2014 Apr;143(4):513-24. doi: 10.1085/jgp.201311118. Epub 2014 Mar 17. PubMed PMID: 24638993; PubMed Central PMCID: PMC3971663.

7: Valentova M, von Haehling S. An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013. Expert Opin Investig Drugs. 2014 Apr;23(4):573-8. doi: 10.1517/13543784.2014.881799. Epub 2014 Feb 4. Review. PubMed PMID: 24490905.

8: Pollesello P. Drug discovery and development for acute heart failure drugs: are expectations too high? Int J Cardiol. 2014 Mar 1;172(1):11-3. doi: 10.1016/j.ijcard.2013.12.136. Epub 2014 Jan 4. PubMed PMID: 24472177.

9: Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Stough WG, Walsh MN, Butler J, Carson PE, Dimarco JP, Hershberger RE, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Starling RC. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail. 2013 Jun;19(6):371-89. doi: 10.1016/j.cardfail.2013.04.002. Review. PubMed PMID: 23743486.

10: Zhang M, Mou T, Zhao Z, Peng C, Ma Y, Fang W, Zhang X. Synthesis and 18F-labeling of the analogues of Omecamtiv Mecarbil as a potential cardiac myosin imaging agent with PET. Nucl Med Biol. 2013 Jul;40(5):689-96. doi: 10.1016/j.nucmedbio.2013.02.013. Epub 2013 Apr 6. PubMed PMID: 23566883.

Additional Information